A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

被引：25
|
作者：
Thondam, S. K. [1 ]
Cuthbertson, D. J. [1 ]
Aditya, B. S. [1 ]
MacFarlane, I. A. [1 ]
Wilding, J. P. [1 ]
Daousi, C. [1 ]
机构：
[1] Univ Liverpool, Dept Obes & Endocrinol, Aintree Univ Hosp NHS Fdn Trust Liverpool, Liverpool L69 3BX, Merseyside, England
来源：
CLINICAL ENDOCRINOLOGY | 2012年 / 77卷 / 04期
关键词：
FOOD-INTAKE; WEIGHT; HUMANS; DAMAGE;
D O I：
10.1111/j.1365-2265.2012.04368.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：635 / 637
页数：3
相关论文
共 50 条
  • [21] Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations
    Kalra, Sanjay
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2014, 64 (03) : 359 - 361
  • [22] The role of glucagon-like peptide 1 (GLP-1) in addictive disorders
    Kruse Klausen, Mette
    Thomsen, Morgane
    Wortwein, Gitta
    Fink-Jensen, Anders
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 625 - 641
  • [23] Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
    E Näslund
    B Barkeling
    N King
    M Gutniak
    JE Blundell
    JJ Holst
    S Rössner
    PM Hellström
    International Journal of Obesity, 1999, 23 : 304 - 311
  • [24] Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics
    Kabahizi, Anita
    Wallace, Briana
    Lieu, Linh
    Chau, Dominic
    Dong, Yanbin
    Hwang, Eun-Sang
    Williams, Kevin W.
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 600 - 624
  • [25] Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?
    Smits, Mark M.
    Holst, Jens J.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2023, 39 (08)
  • [26] Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
    Näslund, E
    Barkeling, B
    King, N
    Gutniak, M
    Blundell, JE
    Holst, JJ
    Rössner, S
    Hellström, PM
    INTERNATIONAL JOURNAL OF OBESITY, 1999, 23 (03) : 304 - 311
  • [27] Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes
    Visentin, Roberto
    Schiavon, Michele
    Goebel, Britta
    Riz, Michela
    Cobelli, Claudio
    Klabunde, Thomas
    Dalla Man, Chiara
    DIABETES OBESITY & METABOLISM, 2020, 22 (04) : 640 - 647
  • [28] Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    Courtney, Hamish
    Nayar, Rahul
    Rajeswaran, Chinnadorai
    Jandhyala, Ravi
    DIABETES METABOLIC SYNDROME AND OBESITY, 2017, 10 : 79 - 87
  • [29] Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
    Fujishima, Yuya
    Maeda, Norikazu
    Inoue, Kana
    Kashine, Susumu
    Nishizawa, Hitoshi
    Hirata, Ayumu
    Kozawa, Junji
    Yasuda, Tetsuyuki
    Okita, Kohei
    Imagawa, Akihisa
    Funahashi, Tohru
    Shimomura, Iichiro
    CARDIOVASCULAR DIABETOLOGY, 2012, 11
  • [30] Glucagon-Like Peptide-1 Analog and Insulin Combination Therapy in the Management of Adults with Type 2 Diabetes Mellitus
    Tzefos, Maria
    Olin, Jacqueline L.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (7-8) : 1294 - 1300
12345